Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | ALB | P02768 | 3/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL6066360 | 0.96 | POLG (0.65) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL211115 | 0.93 | ABL1 (0.57) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL285163 | 0.93 | ABL1 (0.57) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL6913582 | 0.91 | ABL1 (0.55) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL3598 | 0.91 | LMNA (0.62) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL598496 | 0.91 | LMNA (0.62) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL3715526 | 0.91 | LMNA (0.62) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL8094882 | 0.91 | LMNA (0.62) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL21100417 | 0.91 | LMNA (0.62) | POLGPOLBABL1RIN1LMNA | |
| Zalcitabine SCHEMBL3235525 | 0.91 | LMNA (0.62) | POLGPOLBABL1RIN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240355-B1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | CAMBREX BIO SCIENCE ROCKLAND I (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1240355-A4 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6818760-B1 | COMPRISES ADSORBING UNINCORPORATED MOLECULES INTO POROUS HYDROPHOBIC PARTICLES ENCAPSULATED IN A HYDROPHILIC MATRIX; KITS | PROLINX INCORPORATED | 2004-11-16 | — | — | US | disclosed |
| EP-1240355-A1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX, INC. (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6414136-B1 | ADSORPTION OF FLUORESCENT DYE-LABELED MOLECULES NOT INCORPORATED IN POLYMER ONTO HYDROPHOBIC MATERIAL AFTER PASSING THROUGH HYDROPHILIC MATRIX | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6252060-B1 | COMPLEX CONTAINING DIDEOXYGUANOSINE | NEXSTAR PHARMACEUTICALS, INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001025491-A1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001025490-A1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0594677-A4 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0594677-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | NeXstar Pharmaceuticals, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993000910-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1988007854-A1 | NEW ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEM | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0286418-A1 | Anti-retroviral agents and delivery systems for the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1988-10-12 | — | — | EP | disclosed |